Inspire's Q1 2026 print attributes a combined $120 to $150 million FY26 hit to WISeR plus coding uncertainty, six sell-side analysts cut targets through 7 May, and NeuroPace just received a 43% to 47% Medicare reimbursement increase on the same rule cycle.
ONWARD Medical reported Q1 2026 results on 26 May 2026 with EUR 2.0 million in revenue (EUR 1.3 million ARC-EX systems across 100+ clinics, 70 systems supplied including first home-use shipments to US VA patients), two additional ARC-BCI participants bringing the total to seven, and first participant enrolled plus first implant in the Empower BP pivotal study at Craig Hospital, Denver. The company holds EUR 53.4 million in cash before adding over EUR 40 million from the April equity raise, extending runway into Q1 2028.
ABILITY Neurotech, the Geneva-based Wyss Center spinout building Europe's first fully implantable wireless optical-link ECoG brain-computer interface, received Investigational Medical Device Dossier (IMDD) approval from MREC NedMec in the Netherlands on 26 May 2026 to begin the first chronic implantation study of its device in ALS patients at UMC Utrecht under the INTRECOM consortium.
Belgian neurotech ReVision Implant closed an oversubscribed €4 million seed round in May 2026 to bring manufacturing of its Occular cortical vision prosthesis in-house ahead of a first-in-human trial cleared for Q3 2026 (October surgical-window cohort), with broader early-stage trials in blind volunteers expected in summer 2027. The round follows FDA Breakthrough Device Designation granted in March 2026.
Inspire Medical Systems reported Q1 2026 revenue of $204.6 million (up 1.6% year-on-year) on 4 May 2026 and cut full-year 2026 guidance to $825-875 million from the prior $950 million-$1 billion range issued in February. The company attributed approximately $20 million of Q1 impact to CMS WISeR prior authorization and CPT code transition uncertainty. Bank of America analyst Travis Steed downgraded the stock from Neutral to Underperform.
Researchers at Rockefeller University's Laboratory of Neural Systems published evidence in Nature that the ventral premotor cortex hosts the neural substrates of abstract symbolic thought, identifying a brain region that mediates between the higher-thinking prefrontal cortex and the action-executing motor cortex. The finding has direct implications for BCI decoding targets: implants placed at the ventral premotor cortex could potentially decode user intent at a higher level of abstraction than current motor-cortex BCIs.
Synchron co-founder and CEO Tom Oxley publicly criticised Treasurer Jim Chalmers's proposed capital gains tax changes in The Australian on 25 May 2026, joining a growing Australian founder coalition arguing the 2026-27 federal budget reforms would push tech talent and startup equity offshore. The Chalmers budget, handed down 12 May 2026, proposes removing the 50% CGT discount from 1 July 2027 and replacing it with cost-based indexation plus a 30% minimum tax on net capital gains.
The Friday $7.5 million seed round for Neurosoft Bioelectronics is the latest commercial output from a Lausanne-Geneva neurotechnology cluster anchored on EPFL's Neuro-X Institute at Campus Biotech Geneva. The same cluster has produced ONWARD Medical (now NASDAQ-listed brain-spine interface company), MindMaze (Lausanne-founded brain-technology unicorn), and the academic research that China's brain-spine clinical programmes are now structurally copying.
A paraplegic patient who in May 2025 became the world's first to simultaneously receive the invasive Beinao No.1 brain-computer interface and a temporally programmed spinal cord stimulation system has improved from complete to incomplete spinal cord injury (ASIA Grade A to ASIA Grade C) after one year of staged rehabilitation, the Xuanwu Hospital Capital Medical University team disclosed on 22 May 2026.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. One-click unsubscribe. We respect your privacy.